194 related articles for article (PubMed ID: 28126151)
1. 5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Richert-Boe K; Horwitz RI; Jacobsen SJ
Mayo Clin Proc; 2016 Dec; 91(12):1717-1726. PubMed ID: 28126151
[TBL] [Abstract][Full Text] [Related]
2. Risk of Incident Antidepressant-Treated Depression Associated with Use of 5α-Reductase Inhibitors Compared with Use of α-Blockers in Men with Benign Prostatic Hyperplasia: A Population-Based Study Using the Clinical Practice Research Datalink.
Hagberg KW; Divan HA; Nickel JC; Jick SS
Pharmacotherapy; 2017 May; 37(5):517-527. PubMed ID: 28295443
[TBL] [Abstract][Full Text] [Related]
3. Association of Treatment With 5α-Reductase Inhibitors With Time to Diagnosis and Mortality in Prostate Cancer.
Sarkar RR; Parsons JK; Bryant AK; Ryan ST; Kader AK; McKay RR; D'Amico AV; Nguyen PL; Hulley BJ; Einck JP; Mundt AJ; Kane CJ; Murphy JD; Rose BS
JAMA Intern Med; 2019 Jun; 179(6):812-819. PubMed ID: 31058923
[TBL] [Abstract][Full Text] [Related]
4. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
Azoulay L; Eberg M; Benayoun S; Pollak M
JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
[TBL] [Abstract][Full Text] [Related]
5. The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality.
Wallner LP; DiBello JR; Li BH; Van Den Eeden SK; Weinmann S; Ritzwoller DP; Abell JE; D'Agostino R; Loo RK; Aaronson DS; Horwitz RI; Jacobsen SJ
Urology; 2018 Sep; 119():70-78. PubMed ID: 29906480
[TBL] [Abstract][Full Text] [Related]
6. Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer.
Ross AE; Feng Z; Pierorazio PM; Landis P; Walsh PC; Carter HB; Trock BJ; Schaeffer EM
BJU Int; 2012 Sep; 110(5):651-7. PubMed ID: 22289613
[TBL] [Abstract][Full Text] [Related]
7. Impact of 5α-reductase inhibitor and α-blocker therapy for benign prostatic hyperplasia on prostate cancer incidence and mortality.
Van Rompay MI; Curtis Nickel J; Ranganathan G; Kantoff PW; Solomon KR; Lund JL; McKinlay JB
BJU Int; 2019 Mar; 123(3):511-518. PubMed ID: 30216624
[TBL] [Abstract][Full Text] [Related]
8. 5-α reductase inhibitors, benign prostatic hyperplasia, and risk of male breast cancer.
Robinson D; Garmo H; Holmberg L; Stattin P
Cancer Causes Control; 2015 Sep; 26(9):1289-97. PubMed ID: 26109464
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular Outcomes of α-Blockers vs 5-α Reductase Inhibitors for Benign Prostatic Hyperplasia.
Zhang J; Latour CD; Olawore O; Pate V; Friedlander DF; Stürmer T; Jonsson Funk M; Jensen BC
JAMA Netw Open; 2023 Nov; 6(11):e2343299. PubMed ID: 37962887
[TBL] [Abstract][Full Text] [Related]
10. Cardiac Failure Associated with Medical Therapy of Benign Prostatic Hyperplasia: A Population Based Study.
Lusty A; Siemens DR; Tohidi M; Whitehead M; Tranmer J; Nickel JC
J Urol; 2021 May; 205(5):1430-1437. PubMed ID: 33616451
[TBL] [Abstract][Full Text] [Related]
11. Long-term risk of benign prostatic hyperplasia-related surgery and acute urinary retention in men treated with 5-alpha reductase inhibitor versus alpha-blocker monotherapy in routine clinical care.
Bengtsen MB; Heide-Jørgensen U; Borre M; Nørgaard M
Prostate; 2023 Jul; 83(10):980-989. PubMed ID: 37057816
[TBL] [Abstract][Full Text] [Related]
12. Association of 5α-Reductase Inhibitors With Prostate Cancer Mortality.
Björnebo L; Nordström T; Discacciati A; Palsdottir T; Aly M; Grönberg H; Eklund M; Lantz A
JAMA Oncol; 2022 Jul; 8(7):1019-1026. PubMed ID: 35587340
[TBL] [Abstract][Full Text] [Related]
13. Association of clinical benign prostate hyperplasia with prostate cancer incidence and mortality revisited: a nationwide cohort study of 3,009,258 men.
Ørsted DD; Bojesen SE; Nielsen SF; Nordestgaard BG
Eur Urol; 2011 Oct; 60(4):691-8. PubMed ID: 21705134
[TBL] [Abstract][Full Text] [Related]
14. Use of 5-alpha reductase inhibitors and risk of gastrointestinal cancers in men with benign prostatic hyperplasia: A population-based cohort study.
Doherty N; Cardwell C; Murchie P; Hill C; Azoulay L; Hicks B
Int J Cancer; 2024 Aug; 155(4):666-674. PubMed ID: 38554127
[TBL] [Abstract][Full Text] [Related]
15. Rationale and design of the CANARI study: a case-control study investigating the association between prostate cancer and 5-alpha-reductase inhibitors for symptomatic benign prostate hypertrophy by linking SNIIRAM and pathology laboratories in a specific region in France.
Scailteux LM; Balusson F; Vincendeau S; Rioux-Leclercq N; Nowak E
Fundam Clin Pharmacol; 2018 Feb; 32(1):120-129. PubMed ID: 28856711
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S; Mavuduru RS; Panda A; Mathew JL; Agarwal MM; Hwang EC; Lyon JA; Singh SK; Mandal AK
BJU Int; 2019 Jul; 124(1):27-34. PubMed ID: 30681264
[TBL] [Abstract][Full Text] [Related]
17. Use of 5α-reductase inhibitors for benign prostate hypertrophy and risk of high grade prostate cancer: a French population-based study.
Scailteux LM; Rioux-Leclercq N; Vincendeau S; Balusson F; Nowak E; Oger E;
BJU Int; 2019 Feb; 123(2):293-299. PubMed ID: 30025199
[TBL] [Abstract][Full Text] [Related]
18. Clinical progression, acute urinary retention, prostate-related surgeries, and costs in patients with benign prostatic hyperplasia taking early versus delayed combination 5α-reductase inhibitor therapy and α-blocker therapy: a retrospective analysis.
Morlock R; Goodwin B; Gomez Rey G; Eaddy M
Clin Ther; 2013 May; 35(5):624-33. PubMed ID: 23583026
[TBL] [Abstract][Full Text] [Related]
19. Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study.
Murtola TJ; Tammela TL; Määttänen L; Hakama M; Auvinen A
Eur J Cancer; 2007 Mar; 43(4):775-81. PubMed ID: 17251005
[TBL] [Abstract][Full Text] [Related]
20. 5-α reductase inhibitors and the risk of anaemia among men with benign prostatic hyperplasia: A population-based cohort study.
Ayele HT; Douros A; Filion KB
Br J Clin Pharmacol; 2022 Aug; 88(8):3771-3781. PubMed ID: 35301747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]